Diagnosis-to-stabilisation
Financial treatment register
Every identified financial weakness remains linked to an owner, reviewer, measurable outcome, evidence and weekly review until stabilised.
Critical treatments
3
Immediate financial exposure
In implementation
7
Owner execution underway
Pending verification
2
Evidence awaiting reviewer
Stabilised this month
5
Measured outcome sustained
| Treatment | Financial area | Issue | Impact | Risk | Owner / Reviewer | Progress | Status | Target |
|---|---|---|---|---|---|---|---|---|
TRT-2026-001 | Debtors & Collections | Receivables above 90 days | ₹82.0L | Critical | Neha Sharma Finwell Consultant | 42% | In Progress | 25 Aug |
TRT-2026-002 | Inventory | Non-moving stock not measured | ₹31.4L | High | Amit Verma Finwell Consultant | 58% | Under Monitoring | 31 Jul |
TRT-2026-003 | Reporting | Monthly close takes 14 days | Decision delay | High | Finance Head Finwell Consultant | 73% | In Progress | 15 Jul |
TRT-2026-004 | Compliance | Maker-checker evidence incomplete | Penalty exposure | Medium | Compliance Lead CFO | 91% | Completed—Pending Verification | 30 Jun |
TRT-2026-005 | Profitability | Customer-wise margin unavailable | Margin leakage | High | MIS Lead Finwell Consultant | 36% | Treatment Planned | 14 Aug |